AstraZeneca
Two Courts Reject Challenges to Inflation Reduction Act, Marking Major Win for Government
Inflation Reduction Act; IRA; Medicare Drug Negotiation Program; AstraZeneca; federal courts; constitutional challenge; administrative law; Third Circuit Court; CMS; Medicare
AstraZeneca Expands AI Collaboration with SOPHiA GENETICS for Breast Cancer Research
AstraZeneca; SOPHiA GENETICS; AI Factories; breast cancer; predictive models; real-world evidence; genomics; clinical data
AstraZeneca Beats Q2 Estimates on Strong Cancer Drug Sales
AstraZeneca; Q2 2025; cancer drug sales; oncology portfolio; Tagrisso; Imfinzi; Enhertu; financial results
AstraZeneca’s Self-Administered Myasthenia Gravis Drug Gefurulimab Clears Phase 3 Trial
AstraZeneca; gefurulimab; myasthenia gravis; self-administered drug; Phase 3 trial; PREVAIL trial; C5 inhibitor; autoimmune disease; clinical trial; Alexion acquisition
AstraZeneca Highlights Survival Benefit for Tagrisso Combo Amid Competition in Lung Cancer
AstraZeneca; Tagrisso; lung cancer; Johnson & Johnson; EGFR-mutated NSCLC; overall survival; chemotherapy combination; FLAURA2 trial; life-extension benefit
AstraZeneca Unveils $50 Billion U.S. Investment, Including Major Manufacturing Facility in Virginia
AstraZeneca; investment; United States; Virginia plant; manufacturing; R&D; tariffs; chronic diseases; job creation; pharmaceuticals
AstraZeneca Amyloidosis Drug Fails Phase 3 Trials but Shows Potential in Subgroup
AstraZeneca; amyloidosis; anselamimab; Phase 3 trial; clinical trial failure; prespecified subgroup; rare diseases; Alexion; AL amyloidosis; drug development
AstraZeneca’s Baxdrostat Achieves Pivotal Phase 3 Success for Hypertension, Validating $1.3B CinCor Acquisition
AstraZeneca; baxdrostat; CinCor Pharma; hypertension; high blood pressure; phase 3 trial; aldosterone synthase inhibitor; $1.3 billion acquisition; clinical trial win; uncontrolled hypertension; treatment-resistant hypertension
AstraZeneca’s Alexion Signs $825M AAV Capsid Deal with JCR Pharma
AstraZeneca; Alexion; JCR Pharmaceuticals; JUST-AAV; gene therapy; AAV capsid; rare disease; licensing deal; genomic medicines
AstraZeneca and CSPC Enter $5.3B AI-Driven Drug Discovery Pact in China
AstraZeneca; CSPC Pharmaceutical; AI research; drug discovery; chronic diseases; China; $5.3 billion; oral therapies; partnership; R&D investment